Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

The dynamics of the acute pain market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of acute pain. Key players, such as Hyloris Pharmaceuticals/AFT Pharmaceuticals (MAXIGESIC IV), Formosa Pharmaceuticals (APP13007), Vivizon (opiranserin), Concentric Analgesics (vocacapsaicin), Vertex Pharmaceuticals (VX-548), and others, are involved in developing drugs for acute pain treatment.

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Acute Pain Market Report

• As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
• According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021. 
• Leading acute pain companies such as Hyloris Pharmaceuticals, AFT Pharmaceuticals, Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, Neurana Pharmaceuticals, AcelRx Pharmaceuticals, Teikoku Pharma, PainReform, Nevakar, Unither Pharmaceuticals, Aptys Pharmaceuticals, Avenue Pharmaceuticals, and others are developing novel acute pain drugs that can be available in the acute pain market in the coming years.
• The promising acute pain therapies in the pipeline include MAXIGESIC IV (paracetamol + ibuprofen), APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), opiranserin (VVZ-149), vocacapsaicin (CA-008), VX-548, TLC590 (ropivacaine liposomal), PENTHROX (methoxyflurane), NTM-001 (Ketorolac Pre-Mixed Bag), NTM-006, CL-108, CL-H1T, ZALVISO (sufentanil), TPU-006 (dexmedetomidine transdermal system [DMTS]), PRF110, NVK-009 (pregabalin and acetaminophen), and others.
• In March 2022, Formosa Pharmaceuticals completed a Phase III study to treat patients with inflammation and pain after cataract surgery.
• In March 2022, Vertex announced positive results from two Phase II proof-of-concept (POC) studies that investigated VX-548 for acute pain following abdominoplasty or bunionectomy surgery.
• In November 2021, Hyloris Pharmaceuticals announced that the FDA accepted the New Drug Application (NDA) for Maxigesic IV to treat postoperative pain.

Discover which therapies are expected to grab the major acute pain market share @ Acute Pain Market Report

Acute Pain Overview

According to the International Association for the Study of Pain (IASP), acute pain is defined as sudden pain that begins sharp or intense and is a warning sign of disease or a threat to the body. It is usually caused by an injury, surgery, illness, trauma, or painful medical procedure and lasts from a few minutes to less than 6 months. When the underlying cause is treated or healed, acute pain usually goes away. Flu-like symptoms (fever, chills, sore throat, cough), fatigue, numbness, muscle spasms, insomnia, weight loss, anxiety, depression, sharp pain, throbbing, burning, and so on are the most common symptoms associated with acute pain.

Doctors diagnose pain by talking about the patient's acute pain symptoms, the intensity and location of the pain, and any history of injury, surgery, or illness. Young patients may be asked to rate their pain intensity using a scale such as VAS, VRS, NPRS, and so on. Blood tests, X-rays, CT scans, MRI, ultrasound, and other acute pain diagnostic tests are also available.

Acute Pain Epidemiology Segmentation

DelveInsight estimates that there were approximately 100 million cases of acute pain in the US in 2021.

As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million. These cases are expected to grow with a moderate CAGR in the forecast period 2022–2032.

The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases
• Total Diagnosed Incident Cases
• Total Type-specific Cases
• Total Severity-specific Cases
• Total Treated Cases

Download the report to understand which factors are driving acute pain epidemiology trends @ Acute Pain Epidemiological Insights

Acute Pain Treatment Market 

Acute pain treatment is generally tailored to the individual patient's assessment and needs prior to admission. It is typically started by anesthetists during the perioperative period and completed by the surgical team. It entails, if necessary, prior planning with the acute pain service (APS) and the use of protocols for managing specific types of surgeries and identifying at-risk patients. The APS comprises a multidisciplinary team of medical, nursing, and pharmaceutical experts. The APS is heavily involved in the day-to-day management of acute pain following surgery and provides training for medical nursing staff involved in postoperative pain management. Other appropriate services (e.g., physiotherapists) should be used to facilitate early recovery and mobilization.

The current acute pain treatment pattern consists of various approaches classified as pharmacologic and nonpharmacological therapies. Analgesics, which are further classified as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, and others, are among the pharmacological therapies. Benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids are also used to treat acute pain.

Furthermore, acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM) are also examples of nonpharmacological therapies. All of these involve the concept of multimodal analgesia.

To know more about acute pain treatment guidelines, visit @ Acute Pain Management 

Acute Pain Pipeline Therapies and Key Companies

• MAXIGESIC IV (paracetamol + ibuprofen): Hyloris Pharmaceuticals/AFT Pharmaceuticals
• APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension): Formosa Pharmaceuticals
• VVZ-149 (opiranserin): Vivozon
• CA-008 (vocacapsaicin): Concentric Analgesics
• VX-548: Vertex Pharmaceuticals
• TLC590 (ropivacaine liposomal): Taiwan Liposome Company (TLC)
• PENTHROX (methoxyflurane): Medical Developments International (MVP)
• NTM-001 (Ketorolac Pre-Mixed Bag): Neumentum Pharmaceuticals
• NTM-006: Neumentum
• CL-108: Charleston Laboratories
• CL-H1T: Charleston Laboratories
• ZALVISO (sufentanil): AcelRx Pharmaceuticals
• TPU-006 (Dexmedetomidine Transdermal System (DMTS)): Teikoku Pharma USA
• PRF110: PainReform
• NVK-009 (Pregabalin and Acetaminophen): Nevakar

Learn more about the FDA-approved drugs for acute pain @ Drugs for Acute Pain Treatment 

Acute Pain Market Dynamics

The dynamics of the acute pain market is predicted to change in the future due to the improvement in the rise in the number of healthcare spending across the world and rising cases of acute pain. Moreover, growing research and development is increasing the demand for better acute pain diagnosis and acute pain treatment options.

Furthermore, the acute pain market requires new therapies with superior efficacy comparable to opioids but with fewer side effects and drug dependency. As a result, acute pain drugs with novel mechanisms of action and combinations have recently been investigated to overcome the challenges posed by this entity. In addition, clinicians and patients are becoming more aware of multimodal analgesia. Furthermore, increased public awareness creates a lucrative opportunity for therapeutic innovation to propel this acute pain market.

However, several factors are affecting the growth of the acute pain market. One of the major flaws is a lack of effective diagnosis; pain can be a difficult medical problem to diagnose and treat. A variety of events or circumstances can cause it. Many hospitals do not effectively implement pain assessments.

Moreover, existing trial design guidelines must be improved so that future approaches are primarily focused on specific patient groups rather than specific surgical procedures. Specific side effects may jeopardize the drug's recommendations.

Furthermore, in some cases, patients try to ignore the pain and avoid taking proper medication, which causes the condition to deteriorate and turn into chronic pain, which is caused by a lack of healing in the damaged tissue; this impedes both the diagnosis and treatment process. Thus, all these factors mentioned above will likely hamper the acute pain market growth.

Scope of the Acute Pain Market Report

• Therapeutic Assessment: Acute Pain current marketed and emerging therapies
• Acute Pain Market Dynamics: Acute Pain market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Acute Pain Market Access and Reimbursement

Discover more about acute pain drugs in development @ Acute Pain Clinical Trials

Table of Contents

Related Reports

Acute Pain Pipeline

Acute Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute pain companies, including Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, AcelRx Pharmaceuticals, among others.

Acute Pain Epidemiology Forecast

Acute Pain Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic and Acute Pain Market

Chronic and Acute Pain Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic and acute pain companies, including AcelRx Pharmaceuticals, Teikoku Pharma USA, PainReform, Nevakar, among others.

Chronic and Acute Pain Pipeline

Chronic and Acute Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic and acute pain companies, including AcelRx Pharmaceuticals, Teikoku Pharma USA, PainReform, Nevakar, among others.

Moderate to Severe Acute Pain Market

Moderate to Severe Acute Pain Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate to severe acute pain companies, including Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International, among others.

Moderate to Severe Acute Pain Pipeline

Moderate to Severe Acute Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate to severe acute pain companies, including Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Services

Healthcare Consulting 
Healthcare Competitive Intelligence Services 
Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn | Facebook | Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Logo - https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Contact Us:
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 

www.delveinsight.com